|
Study #: 1878 Published: 02/2005 Pages: 283 Full Study Price: US$ 4,100 Per Page Price: US$ 30.00 Diabetes Monitoring Products & Therapies to 2008 - Market Research, Market Share, Market Size, Sales, Demand Forecast, Market Leaders, Company Profiles, Industry Trends US demand for diabetes monitoring products and therapies is expected to grow 9.5 percent annually through 2008. Gains will be driven by more diabetes patients and more aggressive treatments. Best prospects include electrochemical blood glucose test strips, prefilled disposable insulin pen injectors, and TZD and peptide agonist oral anti-diabetic agents. This study analyzes the $11 billion US diabetes monitoring product and therapy industry. It presents historical (1993, 1998, 2003) demand data and forecasts to 2008 and 2013 by product (e.g., blood glucose tests and monitors, diabetes diagnostics, insulin injectors, insulin pumps and accessories, insulin dosages, oral anti-diabetic agents); and by market. The study also considers market environment factors, details industry structure, evaluates company market share and profiles 24 major players including Eli Lilly, GlaxoSmithKline, Bristol-Myers Squibb, Johnson & Johnson, Sanofi-Aventis, Roche, Bayer, Abbott Laboratories, Novo Nordisk, and Medtronic MiniMed.
TABLE OF CONTENTS
SECTION PAGE
INTRODUCTION x
I. EXECUTIVE SUMMARY 1
II. MARKET ENVIRONMENT 4
General 4
Economic Factors 5
Recent Economic Trends 6
Long-Term Economic Projections 7
Demographic Patterns 9
Trends in Health Care 11
Health Insurance 12
National Health Expenditures 15
Medical Providers 18
Patient Activity 21
Diabetes Overview 23
Incidence 24
Type 1 Diabetes 24
Type 2 Diabetes 25
Gestational Diabetes 25
Treatment Costs 27
World Diabetes Conditions 28
III. TECHNOLOGY OVERVIEW 30
General 30
Biosensors 31
Recombinant DNA 33
Stem Cell Research 33
Insulin Dosage Formulations 35
Other Technologies 36
Chiral Chemistry 37
Combinatorial Chemistry 38
Monoclonal Antibodies 39
Nanotechnology 40
IV. PRODUCT OVERVIEW 41
General 41
Market Trends 1993-2003 43
International Markets 45
US Trade 46
World Market Outlook 48
V. BLOOD GLUCOSE MONITORING & DIABETES DIAGNOSTIC PRODUCTS 51
General 51
Blood Glucose Monitoring Products 53
Blood Glucose Test Strips 55
Technologies 56
Producers 59
Electrochemical Test Strips 59
Photometer Reflectance Test Strips 62
Blood Glucose Monitors 63
Monitor Features & Capabilities 64
Point-In-Time Self-Testing Monitors 67
Professional Blood Glucose Monitoring Systems 74
Continuous Self-Testing Monitors 78
Blood Glucose Monitors in Development 81
Blood Glucose Testing Supplies 85
Lancets 86
Lancing Devices 88
Biosensors 91
Diabetes Diagnostic Products 94
Hemoglobin A1c Testing Products 95
Blood Glucose Reagents & Test Kits 98
Microalbumin Testing Products 100
Ketone Testing Products 102
Other Diabetes Diagnostic Products 104
VI. INSULIN DELIVERY SYSTEMS 107
General 107
Insulin Injector Systems 109
Pen Injectors 110
Disposable Pen Injectors 111
Reusable Pen Injectors 114
Syringe & Needle Sets 117
Needleless Jet Injectors 119
Other Insulin Injection Supplies 121
Infectious Waste Disposal Supplies 122
Injection Aids 124
Insulin Pumps & Accessories 127
External Pumps 128
Pump Advantages 130
Pump Disadvantages 130
Producers & Products 130
Implantable Pumps 132
Pump Accessories 133
Insulin Dosage Formulations 135
Types of Insulin 136
Insulin Producers & Products 138
Insulin Vials 140
Insulin Cartridges 141
Inhalation Insulin 143
Oral Insulin 146
Transdermal Insulin 149
Stem Cell Therapies 150
VII. ORAL ANTI-DIABETIC AGENTS 152
General 152
Thiazolidinediones (TZDs) 154
Indications & Actions 155
Products & Producers 156
Troglitazone 157
Pioglitazone HCl & Rosiglitazone Maleate 157
Biguanides 160
Indications & Actions 161
Products & Producers 164
Sulfonylureas 165
Indications & Actions 166
Products & Producers 168
Meglitinides 169
Indications & Actions 169
Products & Producers 170
Enzyme Inhibitors 171
Indications & Actions 172
Products & Producers 173
Peptide Agonists 173
GLP-1 Agonists 174
LAF237 176
MK0431 177
Other Peptide Agonists 177
Non-TZD Peroxisome Proliferator-Activated Receptors 178
Other Oral Anti-Diabetic Agents 180
VIII. MARKETS 185
General 185
Home Health Care Market 188
Primary Health Care Market 190
Other Markets 192
IX. INDUSTRY STRUCTURE 194
General 194
Market Share 195
Competitive Strategies 197
Mergers & Acquisitions 199
Licensing & Related Agreements 200
Regulatory Considerations 207
Research & Development 210
Marketing & Distribution 211
Manufacturing 213
Company Profiles 215
Abbott Laboratories 216
Alkermes Incorporated 220
Aradigm Corporation 223
Aventis SA, see Sanofi-Aventis
Bayer AG 225
Becton, Dickinson and Company 228
Bristol-Myers Squibb Company 231
Cygnus Incorporated 234
Disetronic Group, see Roche Holding Limited
Emisphere Technologies Incorporated 235
GlaxoSmithKline plc 237
IVAX Corporation 239
Johnson & Johnson 240
Kos Pharmaceuticals Incorporated 243
LifeScan Incorporated, see Johnson & Johnson
Lilly (Eli) and Company 245
MannKind Corporation 250
Medtronic Incorporated 251
Merck & Company Incorporated 255
Novartis International AG 257
Novo Nordisk A/S 261
OSI Pharmaceuticals Incorporated 267
Pfizer Incorporated 269
Prosidion Limited, see OSI Pharmaceuticals
Roche Holding Limited 271
Sandoz Generics, see Novartis International AG
Sanofi-Aventis 276
Takeda Pharmaceutical Company Limited 280
Terumo Corporation 282
TheraSense Incorporated, see Abbott Laboratories
LIST OF TABLES
TABLE NUMBER PAGE
SECTION I -- EXECUTIVE SUMMARY
Summary Table 3
SECTION II -- MARKET ENVIRONMENT
1 Macroeconomic Indicators 5
2 Population & Age Distribution 11
3 National Health Expenditures by Type 18
4 Medical Providers 21
5 Patient Activity 23
6 Diabetes Conditions 26
7 Diabetes Expenditures 28
8 World Diabetes Conditions 29
SECTION IV -- PRODUCT OVERVIEW
1 Diabetes Monitoring Products & Therapies Demand
by Product Group 42
2 Diabetes Monitoring Products & Therapies - Demand
Patterns, 1993-2003 45
3 US Trade in Diabetes Monitoring Products & Therapies 47
4 World Diabetes Monitoring Products & Therapies Demand 50
SECTION V -- BLOOD GLUCOSE MONITORING
& DIABETES DIAGNOSTIC PRODUCTS
1 Blood Glucose Monitoring & Diabetes Diagnostic
Products Demand 52
2 Blood Glucose Monitoring Products Demand by Type 55
3 Blood Glucose Test Strips Demand by Type 56
4 Blood Glucose Test Strips - Selected Characteristics 58
5 Electrochemical (EC) Blood Glucose Test Strips Demand 61
6 Photometer Reflectance (PR) Test Strips Demand 63
7 Blood Glucose Monitors Demand by Type 64
8 Blood Glucose Monitors - Selected Characteristics 67
9 Point-In-Time Self-Testing Blood Glucose Monitors Demand 68
10 Professional Use Blood Glucose Monitors Demand 75
11 Continuous Blood Glucose Monitors Demand 80
12 Blood Glucose Testing Supplies Demand by Type 85
13 Lancets Demand 88
14 Lancing Devices Demand 91
15 Biosensors Demand 94
16 Diabetes Diagnostic Products Demand by Type 95
17 Hemoglobin A1c Testing Products Demand 98
18 Blood Glucose Reagents & Test Kits Demand 100
19 Microalbumin Testing Products Demand 102
20 Ketone Testing Products Demand 104
21 Other Diabetes Diagnostic Products Demand 106
SECTION VI -- INSULIN DELIVERY SYSTEMS
1 Insulin Delivery Systems Demand by Type 108
2 Insulin Injector Systems Demand 110
3 Insulin Pen Injector Demand 111
4 Disposable Insulin Pen Injector Demand 113
5 Reusable Insulin Pen Injector Demand 116
6 Insulin Syringe & Needle Set Demand 118
7 Needleless Insulin Jet Injector Demand 121
8 Other Insulin Injector Supply Demand 122
9 Insulin Pump & Accessory Demand 128
10 External Insulin Pump Demand 129
11 Implantable Insulin Pump Demand 133
12 Insulin Pump Accessory Demand 135
13 Insulin Demand by Dosage Formulation 136
14 Insulin Vial Demand 141
15 Insulin Cartridge Demand 142
SECTION VII -- ORAL ANTI-DIABETIC AGENTS
1 Oral Anti-Diabetic Agents Demand 153
2 Thiazolidinediones (TZDs) Demand 155
3 Biguanides Demand 161
4 Sulfonylureas Demand 166
5 Meglitinides Demand 169
6 Enzyme Inhibitors Demand 171
7 Peptide Agonist Demand 174
8 Non-TZD PPARs Demand 180
9 Other Oral Anti-Diabetic Agents Demand 184
SECTION VIII -- MARKETS
1 Diabetes Monitoring Products & Therapies
Demand by Market 187
2 Home Health Care Market -- Diabetes Monitoring Products
& Therapies 190
3 Primary Health Care Market -- Diabetes Monitoring Products
& Therapies 192
4 Other Markets -- Diabetes Monitoring Products & Therapies 193
SECTION IX -- INDUSTRY STRUCTURE
1 Diabetes Monitoring Products & Therapies Sales
by Company, 2003 196
2 Selected Acquisitions & Divestitures 200
3 Selected Cooperative Agreements 202
LIST OF CHARTS
CHART NUMBER PAGE
SECTION IV -- PRODUCT OVERVIEW
1 Diabetes Monitoring Products & Therapies Demand
by Product Group, 2003 43
SECTION V -- BLOOD GLUCOSE MONITORING
& DIABETES DIAGNOSTIC PRODUCTS
1 Blood Glucose Monitoring & Diabetes Diagnostic Products
Demand by Type, 2003 53
SECTION VI -- INSULIN DELIVERY SYSTEMS
1 Insulin Delivery Systems Demand by Type, 2003 109
SECTION VII -- ORAL ANTI-DIABETIC AGENTS
1 Oral Anti-Diabetic Agents Demand by Type, 2003 154
SECTION VIII -- MARKETS
1 Diabetes Monitoring Products & Therapies Demand
by Market, 2003 187
SECTION IX -- INDUSTRY STRUCTURE
1 Diabetes Monitoring Products & Therapies Market
Share, 2003 197
You may view the complete table of contents without charge and select individual records for purchase ($30.00 each) or purchase the complete study.
Home About Freedonia Contact Freedonia Search Studies Browse Catalog The Freedonia Group - The First Choice In Industry Research8 © Copyright 2003 The Freedonia Group, Inc.
|